Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALURNASDAQ:FEMYNASDAQ:QNRXNYSE:RVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.69-0.7%$2.57$2.15▼$88.75$20.06M-0.47784,837 shs9,564 shsFEMYFemasys$0.84-1.1%$1.07$0.69▼$1.80$21.48M-2.62368,643 shs23,581 shsQNRXQuoin Pharmaceuticals$8.52+0.4%$7.26$5.01▼$54.95$5.01M1.44245,869 shs2,688 shsRVPRetractable Technologies$0.66-2.4%$0.70$0.56▼$1.21$19.84M1.3968,926 shs3,923 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-0.51%-5.73%+14.08%+12.14%-91.24%FEMYFemasys+6.25%+6.24%-21.31%-39.29%-21.31%QNRXQuoin Pharmaceuticals+1.98%-5.72%+38.64%-17.82%-67.19%RVPRetractable Technologies+0.49%+0.86%-10.33%-8.89%-42.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.8173 of 5 stars3.54.00.00.00.63.30.6FEMYFemasys3.6381 of 5 stars3.53.00.00.04.12.51.3QNRXQuoin Pharmaceuticals1.363 of 5 stars0.05.00.00.03.80.00.6RVPRetractable Technologies1.2065 of 5 stars0.03.00.00.01.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 3.00Buy$22.83741.01% UpsideFEMYFemasys 3.00Buy$8.67919.73% UpsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ARVPRetractable Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNRX, ALUR, FEMY, and RVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/27/2025ALURAllurion TechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.50 ➝ $2.503/21/2025ALURAllurion TechnologiesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/21/2025ALURAllurion TechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.503/19/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.003/13/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$28.30M0.72N/AN/A($36.95) per share-0.07FEMYFemasys$1.70M12.78N/AN/A$0.85 per share1.00QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ARVPRetractable Technologies$33.75M0.60$0.01 per share48.25$3.31 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$80.61M-$12.50N/AN/AN/A-71.24%N/A-56.75%8/12/2025 (Estimated)FEMYFemasys-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%8/14/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$48.81N/AN/AN/AN/A-125.60%-64.77%8/14/2025 (Estimated)RVPRetractable Technologies-$7.01M-$0.77N/A∞N/A-41.11%-17.15%-9.33%N/ALatest QNRX, ALUR, FEMY, and RVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ALURAllurion Technologies-$1.53$0.43+$1.96$0.20$5.50 million$5.58 million5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million3/27/2025Q4 2024FEMYFemasys-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 million3/26/2025Q4 2024ALURAllurion Technologies-$5.00-$7.00-$2.00-$7.95$5.60 million$5.59 million3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.332.09FEMYFemasys0.863.943.26QNRXQuoin PharmaceuticalsN/A3.023.02RVPRetractable Technologies0.018.575.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%FEMYFemasys65.27%QNRXQuoin Pharmaceuticals8.63%RVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%FEMYFemasys11.54%QNRXQuoin Pharmaceuticals3.70%RVPRetractable Technologies57.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.46 million2.01 millionOptionableFEMYFemasys3025.55 million20.08 millionNot OptionableQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableRVPRetractable Technologies24029.94 million13.47 millionOptionableQNRX, ALUR, FEMY, and RVP HeadlinesRecent News About These Companiesretractable technologies appoints new auditor after mergerJune 8, 2025 | investing.comThomas J. Shaw Buys 86,014 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 17, 2025 | insidertrades.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025 | RVP Stock NewsMay 15, 2025 | gurufocus.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025May 15, 2025 | businesswire.comRetractable Technologies, Inc. (NYSE:RVP) CEO Buys $10,037.25 in StockMay 15, 2025 | insidertrades.comThomas J. Shaw Purchases 22,620 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 7, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Buys 16,165 Shares of StockApril 24, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Purchases 33,524 Shares of StockApril 15, 2025 | insidertrades.comLittle Elm's Retractable Technologies announces 7% workforce reduction due to tariffsApril 11, 2025 | starlocalmedia.comRetractable Technologies cuts workforce to reduce reliance on China amid trade warApril 11, 2025 | drugdeliverybusiness.comRetractable Technologies announces 7% workforce reductionApril 11, 2025 | markets.businessinsider.comRetractable Technologies, Inc. Announces Reduction in WorkforceApril 10, 2025 | businesswire.comRetractable Technologies, Inc. Reports Results for 2024March 28, 2025 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | investing.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | businesswire.comThomas J. Shaw Buys 18,227 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockFebruary 5, 2025 | insidertrades.comRetractable Technologies CEO Thomas Shaw acquires $14,082 in stockFebruary 4, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Acquires $10,080.45 in StockJanuary 29, 2025 | insidertrades.comRetractable technologies CEO Thomas Shaw acquires shares worth $10,105January 28, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Purchases $22,707.36 in StockJanuary 24, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, ALUR, FEMY, and RVP Company DescriptionsAllurion Technologies NYSE:ALUR$2.69 -0.02 (-0.74%) As of 10:33 AM EasternAllurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Femasys NASDAQ:FEMY$0.84 -0.01 (-1.08%) As of 10:39 AM EasternFemasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Quoin Pharmaceuticals NASDAQ:QNRX$8.52 +0.03 (+0.35%) As of 10:15 AM EasternQuoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Retractable Technologies NYSE:RVP$0.66 -0.02 (-2.37%) As of 10:15 AM EasternRetractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alibaba’s Dip Is a Gift—Here’s the Price That Matters GameStop Turns a Profit, But Core Business Keeps Shrinking Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
